Oragenics Inc. (OGEN) Stock Price

OGENStock

$0.43−66.55%52W

Market Cap$1.96M

P/E—

PEG Ratio-8.96

Div yield—

Beta1.28

OGEN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-43.51%

Price vs S&P 500 (4W)-14.88%

PEG Ratio-8.96

VGM Score41.45

Book Value / Share (Quarterly)$0.81

P/TBV (Annual)0.71x

Cash Flow / Share (Quarterly)$-2.26

Price vs S&P 500 (YTD)-56.40%

Gross Margin (TTM)61.29%

Net Profit Margin (TTM)-19750.00%

EPS (TTM)$-5.61

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-5.61

EPS (Annual)$-4.56

ROI (Annual)-115.67%

Gross Margin (Annual)60.64%

Net Profit Margin (5Y Avg)-17097.31%

Cash / Share (Quarterly)$0.86

ROA (Last FY)-97.76%

EBITD / Share (TTM)$-3.37

ROE (5Y Avg)-219.39%

Operating Margin (TTM)-20250.00%

Cash Flow / Share (Annual)$-2.16

P/B Ratio0.53x

P/B Ratio (Quarterly)0.71x

Net Income / Employee (Annual)$-3,280,800

EV / Revenue (TTM)-47.55x

Net Interest Coverage (TTM)-15.18x

ROA (TTM)-91.83%

EPS Incl Extra (Annual)$-4.56

Current Ratio (Annual)5.64x

Quick Ratio (Quarterly)2.12x

3-Month Avg Trading Volume0.03M

52-Week Price Return-66.55%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.53

P/S Ratio (Annual)52.12x

Asset Turnover (Annual)0.01x

52-Week High$1.45

Operating Margin (5Y Avg)-17266.36%

EPS Excl Extra (Annual)$-4.56

Tangible BV CAGR (5Y)15.55%

26-Week Price Return-33.60%

Quick Ratio (Annual)4.73x

13-Week Price Return-20.87%

Total Debt / Equity (Annual)0.03x

Current Ratio (Quarterly)3.01x

Enterprise Value$-1.90M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-38.69%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)-54862.52%

Cash / Share (Annual)$1.97

3-Month Return Std Dev46.31%

Gross Margin (5Y Avg)48.54%

Net Income / Employee (TTM)$-2,541,800

ROE (Last FY)-118.85%

Net Interest Coverage (Annual)-7.12x

EPS Basic Excl Extra (Annual)$-4.56

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.61

Receivables Turnover (Annual)0.00x

ROI (TTM)-57.15%

P/S Ratio (TTM)49.06x

Pretax Margin (5Y Avg)-17097.31%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$6.43

Price vs S&P 500 (52W)-82.08%

Year-to-Date Return-44.47%

5-Day Price Return-2.84%

EPS Normalized (Annual)$-4.56

ROA (5Y Avg)-276.76%

Net Profit Margin (Annual)-54862.52%

Month-to-Date Return-11.57%

Cash Flow / Share (TTM)$-4.69

EBITD / Share (Annual)$-4.34

Operating Margin (Annual)-55524.33%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-206.03%

LT Debt / Equity (Quarterly)2.38x

EPS Basic Excl Extra (TTM)$-5.61

P/TBV (Quarterly)1.42x

P/B Ratio (Annual)0.39x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)-19750.00%

Book Value / Share (Annual)$1.94

Price vs S&P 500 (13W)-23.56%

Beta1.28x

P/FCF (Annual)16.35x

Revenue / Share (TTM)$0.00

ROE (TTM)-59.11%

52-Week Low$0.43

mGradeC

vgmGradeC

OGEN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.14

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
OGENOragenics Inc.	—	—	C	49.1x	—	61.3%	—	$0.43
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Oragenics Inc.

Oragenics Inc develops nasal-delivery pharmaceutical treatments for neurology and infectious diseases. The company's lead candidate, ONP-002, is a synthetic neurosteroid designed to cross the blood-brain barrier and rapidly reduce inflammation, swelling, and oxidative stress. ONP-002 is being developed to treat concussions by restoring proper blood flow.